title: Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A1chieve study.
abstract: BACKGROUND
  The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.
  
  
  METHODS
  Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kolkata, India.
  
  
  RESULTS
  A total of 576 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 417), insulin detemir (n = 70), insulin aspart (n = 55), basal insulin plus insulin aspart (n = 19) and other insulin combinations (n = 15). At baseline, glycaemic control was poor for both insulin naïve (mean HbA1c: 8.3%) and insulin user (mean HbA1c: 8.6%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: -1.3%, insulin users: -1.4%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
  
  
  CONCLUSIONS
  Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
authors.affiliation: KPC Medical College and Hospital, Kolkata, India.
authors.forename: Anirban
authors.initials: A
authors.lastname: Majumder
authors.affiliation: GD hospital & Diabetes Institute, Kolkata, India ; Sun Valley Diabetes & Endocrine Centre, Guwahati, India.
authors.forename: Awadhesh Kumar
authors.initials: AK
authors.lastname: Singh
authors.affiliation: Fortis Hospital, Bangalore, India.
authors.forename: Kalyan Kumar
authors.initials: KK
authors.lastname: Gangopadhyay
authors.affiliation: Novo Nordisk India Pvt. Ltd., Bangalore, India.
authors.forename: Ranjini
authors.initials: R
authors.lastname: Sen
authors.affiliation: Novo Nordisk India Pvt. Ltd., Bangalore, India.
authors.forename: Raman
authors.initials: R
authors.lastname: Shetty
authors.affiliation: GD hospital & Diabetes Institute, Kolkata, India.
authors.forename: Sujoy
authors.initials: S
authors.lastname: Majumdar
keywords: A1chieve study; Kolkata; insulin analogues; type 2 diabetes mellitus